Matrix Metalloproteinase-2 Conditions Human Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12- and OX40L-Dependent Pathway  by Godefroy, Emmanuelle et al.
Cancer Cell
ArticleMatrix Metalloproteinase-2 Conditions Human
Dendritic Cells to Prime Inflammatory TH2 Cells
via an IL-12- and OX40L-Dependent Pathway
Emmanuelle Godefroy,1 Olivier Manches,1 Brigitte Dre´no,2 Tsivia Hochman,1 Linda Rolnitzky,1 Nathalie Labarrie`re,2
Yannick Guilloux,2 Judith Goldberg,1,3 Francine Jotereau,2,3 and Nina Bhardwaj1,*
1New York University Langone Medical Center, Cancer Institute, New York, NY, USA
2INSERM U892, F-44093, Nantes, France
3These authors contributed equally to this work
*Correspondence: nina.bhardwaj@nyumc.org
DOI 10.1016/j.ccr.2011.01.037SUMMARYMatrix metalloproteinase-2 (MMP-2) is a proteolytic enzyme degrading the extracellular matrix and overex-
pressed by many tumors. Here, we documented the presence of MMP-2-specific CD4+ T cells in tumor-infil-
trating lymphocytes (TILs) from melanoma patients. Strikingly, MMP-2-specific CD4+ T cells displayed an
inflammatory TH2 profile, i.e., mainly secreting TNF-a, IL-4, and IL-13 and expressing GATA-3. Furthermore,
MMP-2-conditioned dendritic cells (DCs) primed naı¨ve CD4+ T cells to differentiate into an inflammatory TH2
phenotype through OX40L expression and inhibition of IL-12p70 production. MMP-2 degrades the type I IFN
receptor, thereby preventing STAT1 phosphorylation, which is necessary for IL-12p35 production. Active
MMP-2, therefore, acts as an endogenous type 2 ‘‘conditioner’’ and may play a role in the observed preva-
lence of detrimental type 2 responses in melanoma.INTRODUCTION
A large array of human melanoma-associated antigens (MAA)
has been identified and used in various immunization strategies
to treat cancer patients. However, despite significant induction
of tumor-specific T cells (Coulie and van der Bruggen, 2003;
Rosenberg, 2004), the therapeutic efficacy of these approaches
has been suboptimal indicating a need for improving current
strategies. Possible explanations for failure (Loose and Van de
Wiele, 2009) include malignant cells producing immunosuppres-
sive cytokines (IL-10, TGF-b, IL-6, and M-CSF), prostaglandins,
and vascular endothelial growth factor thereby skewing the
immune response toward type 2 or regulatory T cells and delete-
riously modulating the differentiation, maturation, and function of
antigen-presenting cells (APCs). Furthermore, malignant cells
that chronically stimulate infiltrating T cells can actively exhaustSignificance
Several melanoma-associated antigens (MAA) have been targ
However, the therapeutic efficacy of these approaches rem
Because MMP-2 activity is critical for melanoma progression
show that MMP-2 is an immunogenic tumor antigen. However
inflammatory TH2 profile. MMP-2-conditoned DCs prime TH2 r
create a TH2 skewing microenvironment in a bystander fashion
improving immune responses toward a more effective TH1 re
antigen in melanoma.and eliminate T cells through expression of molecules such as
FasL, PDL-1, or RCAS1. Finally, due to immune pressure, immu-
noresistant tumor cell variants emerge through selection of
mutants with reduced antigenicity. This can affect the expres-
sion/function of molecules implicated in antigen processing
and presentation or the expression of tumor antigens them-
selves (Hirohashi et al., 2009; Yee et al., 2000).
A way to circumvent this latter limitation would be to vaccinate
against immunogenic proteins whose expression is critical for
tumor growth and/or invasiveness. The matrix metalloprotei-
nase-2 (MMP-2), overexpressed in many tumors including mela-
noma, may be such an antigen. MMP-2 is a proteolytic enzyme
that degrades numerous components of extracellular matrix
such as collagens, laminin, or fibronectin and contributes to
cell migration by clearing the surrounding extracellular matrix
and basement membrane barriers. MMP-2 overexpression haseted in immunization strategies to treat melanoma patients.
ains limited, indicating an urgent need for improvement.
, it represents an interesting target for vaccine therapy. We
, MMP-2-specific CD4+ T lymphocytes display a suboptimal
esponses against several MAA, suggesting that MMP-2 can
. Elucidation of the underlying mechanisms opens the way to
sponse, and highlights the potential of MMP-2 as a target
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Figure 1. MMP-2-Specific CD4+ T Cell
Responses in Melanoma Patients
TILs from representative melanoma patient M186
(A) or from 31 unselected patients (B) were stimu-
lated with the MMP-2 peptide pool (2 mM) for 6 hr
and assessed for cytokine production by intracel-
lular staining. Percentage of secreting cells upon
peptide stimulation was considered specific/
positive when it exceeded by more than 2-fold
the background (cytokine-secreting cells in the
absence of stimulation) and had more than 0.5%
of responding cells (after background subtraction)
for at least one cytokine. See also Figure S1 for
MMP-2-derived peptides and patient survival
analysis.
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MMP-2-Dependent Immune Deviation in Melanomabeen associated with tumor progression. Indeed, MMP-2
modulates various oncogenic processes such as angiogenesis
(Brooks et al., 1998; Itoh et al., 1998) and tumor dissemination
(Kessenbrock et al., 2010; Liotta et al., 1980; Westermarck and
Kahari, 1999).
We previously identified MMP-2 as a melanoma-associated
antigen (MAA) recognized by HLA-A*0201-restricted CD8+
tumor-infiltrating lymphocytes (TILs) (Godefroy et al., 2005).
Because MMP-2 activity is critical for melanoma progression,
MMP-2 is a promising tumor antigen to target in immunotherapy
against malignant melanoma. Accordingly, several patients
administered CD8+ T cells that recognize this epitope among
others have remained tumor-free up to 15 years after treatment
(Godefroy et al., 2005; Khammari et al., 2007).
As CD4 help is essential for generating effective antitumor
immunity we evaluated whether MMP-2 could also be recog-
nized by CD4+ T cells. Here, we characterize these cells and
identify mechanisms by which they are generated.
RESULTS
MMP-2-Specific CD4+ T Cell Responses in Melanoma
Patients
Whether CD4+ T cells recognize MMP-2-derived epitopes has
not previously been established. We used a pool of 20 amino
acid long, partially overlapping peptides spanning the entire
sequence of MMP-2 (see Figure S1A available online) to evaluate
specific responses in TILs derived from melanoma patients, in
some of whom we had previously detected MMP-2-specific334 Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc.CD8+ T cells infiltrating their tumors and
whose tumor cells produced MMP-2
protein (Godefroy et al., 2005). Strikingly,
MMP-2-specific CD4+ T cells were found
in 13 out of 31 unselected TIL populations
(Figures 1A and 1B). Among these 13
responders, the percentage of cells
secreting TNF-a upon stimulation ranged
from 0.04% to 2.12% (mean = 0.78% ±
0.53) and IL-4 from 1.17% to 4.91%
(mean = 2.44% ± 1.21). Very few cells
produced IFN-g and IL-2 (Figures 1A
and 1B). Therefore, more than 40% oftested TILs contained MMP-2-specific CD4+ T cells preferen-
tially secreting IL-4 and TNF-a.
To try and evaluate whether these TILs played any therapeutic
role, we assessed the clinical outcome of patients who had CD4+
TILs targeting MMP-2. Survival status was available for 21 of
these patients. Twelve patients displayed MMP-2-specific
CD4+ T cell responses and demonstrated a trend toward a
poorer clinical outcome compared with patients with no detect-
able MMP-2 responses (Figure S1B). However, the observed
difference in patient’s survival was not statistically significant
(p = 0.121).
MMP-2-Specific CD4+ T Cell Responses
in Healthy Donors
To further study and characterize MMP-2-specific CD4+ T cells,
we stimulated circulating isolated CD4+ cells from 16 healthy
donors with the same pool of MMP-2 peptides. Twelve days
later, cultures were assessed for MMP-2-specific CD4+ T cells
by monitoring intracellular cytokine staining upon stimulation
with the peptide pool. We derived 14MMP-2-reactive polyclonal
populations (Figures 2A and 2B). Among these 14 responders
and upon peptide restimulation, the percentage of cells
secreting TNF-a ranged from 0 to 2.8% (mean = 0.46% ±
0.69), IFN-g from 0 to 0.44% (mean = 0.07% ± 0.11), IL-2 from
0 to 0.24% (mean = 0.06% ± 0.06), IL-4 from 0.55 to 4.93%
(mean = 1.69% ± 1.3) and IL-13 from 0 to 1.21% (mean =
0.15% ± 0.31) (Figure 2B). No MMP-2-specific CD4+ T cells
secreted IL-10 and very few cells secreted type 1 cytokines
(Figures 2A and 2B). To determine whether MMP-2 responses
Figure 2. MMP-2-Specific Polyclonal CD4+
T Cell Responses in Healthy Donors
(A) Isolated CD4+/CD25- T cells from 16 healthy
donors were individually stimulated with the
MMP-2 peptide pool (2 mM) pulsed on the
irradiated (35 grays) autologous CD4- fraction.
12 days later, cells were restimulated, in an auto-
presentation manner (no APCs), with the same
peptides (2 mM) for 6 hr, and assessed for cytokine
production by intracellular staining. Density plots
represent cytokine production by representative
donor HD9759.
(B) Percentages of MMP-2-specific CD4+ T cells
(% of producing CD4+ cells after peptide
stimulation –%of producing CD4+ cells nonstimu-
lated [background]) are shown for all donors.
Percentage of secreting cells upon peptide stimu-
lation was considered specific/positive when it
exceeded by more than 2-fold the background
(cytokine-secreting cells in the absence of peptide
stimulation) and had more than 0.5% of respond-
ing cells (after background subtraction) for at least
one cytokine.
(C) Ex vivo PBMCs from six healthy donors were
stimulated by adding the MMP-2 peptide pool
(2 mM) onto the cells (no specific APCs were tar-
geted). The gating strategy for visualizing memory
CD4+ T cells is shown on the left plot. Density plots
showing cytokine production of CD4+/CD45RO+/
CD62L- memory cells are represented for repre-
sentative donor HD7957. Percentages of produc-
ing cells among CD4+/CD45RO+ gated cells are
indicated.
(D) MMP-2-specific memory CD4+ T cell re-
sponses for all donors are represented. CD4+/
CD45RA+/CD62L+ naı¨ve cells derived from
healthy (n = 6) and cord blood (n = 9) donors
were used as controls.
See also Figure S2.
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healthy donors with MMP-2 peptides and measured their
cytokine responses. Responding gated CD4+ memory T cells
(CD4+/CD45RO+/CD62L-) secreted IL-4 (mean = 1.09% ± 0.61
of CD4+/CD45RO+ cells), but none of the other cytokines (Fig-
ures 2C and 2D). The absence of detectable TNF-a responses
is likely to be due to the small percentages of MMP-2-specific
CD4+ T cells, producing cytokine below the detection threshold.
Gated naı¨ve CD4+/CD45RA+/CD62L+ T cells, derived either
from healthy donors or cord blood, were used as controls, and
failed to respond to the MMP-2 peptides (Figure 2D). Therefore,Cancer Cell 19, 333–34MMP-2-specific CD4+ T cells can be
frequently expanded from normal donors
and secrete primarily TNF-a and IL-4, but
little type 1 cytokines and no IL-10,
consistent with an inflammatory TH2
profile (Ito et al., 2005; Soumelis et al.,
2002) acquired in vivo.
To more accurately characterize
MMP-2-specific CD4+ T cell differentia-
tion state, T cell clones were generated
in vitro from healthy donors (Figure S2B).Nineteen CD4+ T cell clones responding to the MMP-2 peptide
pool were subsequently characterized (as exemplified by clone
HD9828/52) for epitope specificity (Figure S3A), CD4/CD8,
TCR Vb expression (Figure S3B) and HLA class-II isotype restric-
tion (Figure S3C). Results for all CD4+ T cell clones are shown in
Table S1. We looked for production of TNF-a, IL-4, and IFN-g
upon stimulation with individual peptides separately to assess
epitope specificities. Nineteen CD4+ T cell clones recognized
eleven distinct MMP-2-derived peptides, within the following
amino acid positions: 1–20, 11–30, 21–40, 41–60, 161–180,
361–380, 551–570, 571–590, 601–620, 621–640, and 631–6506, March 15, 2011 ª2011 Elsevier Inc. 335
Figure 3. MMP-2-Specific CD4+ T Cells
Display an Inflammatory TH2 Phenotype
(A and B) CD4+ T cell clones were stimulated with
peptides (2 mM) for 6 hr. Cytokine production was
assessed by intracellular staining (clone HD5950/
MC2/43 is shown as an example) (A). The results
for the 19 MMP-2-specific CD4+ clones are also
shown (B, black bars). Three Melan-A/MART-1-
and eight NY-ESO-1-specific CD4+ T cell clones
were stimulated with peptides (2 mM) for 6 hr
before intracellular staining for cytokines (B, gray
and white bars, respectively). Results are shown
as mean ± SD.
(C and D) T-bet and GATA-3 expression was
measured by intracellular staining of MMP-2-
(n = 19), Melan-A/MART-1- (n = 3) and NY-ESO-
1-specific CD4+ T cell clones (n = 8). Histogram
plots show a representative example for one NY-
ESO-1-specific CD4+ T cell clone (HD3014/1)
and one MMP-2-specific CD4+ T cell clone
(HD5950/33).
(C) Isotype control is represented in tinted gray.
(D) MFIs for all CD4+ T cell clones are represented.
Cord blood-derived CD4+/CD45RA+/CD62L+
naı¨ve cells (n = 9) were used as a negative control.
For each cytokine or transcription factor, analyses
of variance were used to compare T cells specific
for MMP-2, Melan-A and NY-ESO-1, and t tests
were used for pairwise comparisons between
groups. p values % 0.025 (*) were considered
statistically significant using a Bonferroni correc-
tion for two comparisons.
See also Figure S3 and Table S1.
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were used to confirm clonality and distinguished at least 13
distinct clones among the original 19 CD4+ T cell clones (Fig-
ure S3B; Table S1), as >99% of each culture expressed only
one Vb chain (not shown). Blocking antibodies against HLA class
II isotypes showed that most of theMMP-2-specific T cell clones
were HLA-DR restricted (Figure S3C; Table S1).
To assess the physiological relevance of MMP-2-derived
epitope presentation, CD4+ T cells from healthy donors were
stimulated with autologous DCs loaded with whole MMP-2 pro-
tein. Twelve days later, we tested T cell responses to the peptide
pool. Donors HD6026 and HD6028 had 0.12% and 0.17%of cells
secreting IFN-g as well as 0.73% and 1.99% secreting IL-4,
respectively (Figure S3D). These results showed, on the one336 Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc.hand, that the whole protein is naturally
processed and presented by DCs to
T cells and, on the other hand, that MMP-
2-specific human CD4+ T cells preferen-
tially secrete IL-4 upon DC stimulation.
MMP-2-Specific CD4+ T Cells
Display an Inflammatory TH2
Phenotype
Because the majority of MMP-2-specific
CD4+ T cell clones, upon peptide stimula-
tion, secreted more IL-4 and TNF-a than
IFN-g (Figure S3A and not shown), wetested them for production of a broader panel of cytokines to
further assess their cytokine profile. MMP-2-specific T cell
clones, as shown by the representative clone HD5950/MC2/43
(Figure 3A) or the 19 clones (Figure 3B), secreted mainly TNF-
a (mean = 38.2% of secreting cells, after background subtrac-
tion), IL-4 (mean = 23.5%), and IL-13 (mean = 19.7%), but fewer
cells produced IFN-g (mean = 6.2%) and IL-2 (mean = 5.7%).
This profile again corresponds to an inflammatory TH2 pheno-
type (Ito et al., 2005; Soumelis et al., 2002).
Because of the unique inflammatory TH2 profile of MMP-2-
specific CD4+ T cells, we next examined CD4+ T cell responses
to other MAA, under the same conditions. CD4+ T cells from
healthy donors were stimulated with overlapping 20 amino acid
long peptides spanning the length of the differentiation antigen
Figure 4. Effect of MMP-2 Enzyme on
Specific CD4+ T Cell Differentiation
Cord blood-derived CD4+/CD25- cells from 11
donors were stimulated with irradiated autologous
CD4- cells loaded either with active MMP-2, heat-
inactivated (HI) MMP-2 or with MMP-2 preincu-
bated with a specific inhibitor (+ I). After 15 days,
CD4+ T cells were stimulated with the MMP-2
peptide pool (2 mM) for 6 hr before intracellular
staining of cytokines.
(A) Density plots representing cytokine production
by CD4+ T cells are shown for the representative
donor CB35 primed to MMP-2 either in its active
form or after heat-inactivation. Numbers indicate
percentages of cytokine-producing cells upon
MMP-2 peptide stimulation.
(B) Cytokines secreted by MMP-2-specific CD4+
T cells primed to inactive protein or peptides for
all donors are shown and compared with MMP-
2-specific CD4+ T cells generated after priming
with active MMP-2. MMP-2 enzymatic activity
was controlled (Figure S5C and S5D).
For each cytokine, three paired t tests were used to
compare activeMMP-2 to heat inactivated MMP-2,
to MMP-2+I, and to MMP-2 peptides. p values %
0.0167 (*) were considered statistically significant
using aBonferroni correction for threecomparisons.
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sequences. Antigen-specific T cells were then enriched before
generating antigen-specific CD4+ T cell clones. We obtained
three CD4+ T cell clones specific for Melan-A/MART-1 (recog-
nizing the epitopes P21-40, P51-70, and P61-80) and eight for NY-
ESO-1 (recognizing P61-80, P81-100, P119-143, P131-160, P139-160,
and P161-180). Upon peptide stimulation, these clones secreted
TNF-a (mean = 84.8% of secreting cells after background sub-
traction), IFN-g (mean = 76.1%; overall ANOVA p % 0.0001,
compared with MMP-2-specific T cell clones), IL-2 (mean =
35.0%; overall ANOVA p % 0.0001 compared with MMP-2-
specific T cell clones), and IL-13 (mean = 58.5%), but low
amounts of IL-4 (mean = 14.1%) (Figure 3B). To further charac-
terize and compare MMP-2-, Melan-A/MART-1- and NY-ESO-
1-specific T helper profiles, clones were stained for type 1 and
type 2-associated transcription factors, T-bet and GATA-3,
respectively. MMP-2-specific T cell clones expressed GATA-3
(mean MFI (mean fluorescence intensity) = 105) and insignificant
levels of T-bet (mean MFI = 5.5), while Melan-A/MART-1- and
NY-ESO-1-specific T cell clones expressed T-bet (mean MFI =
16.6) and lower amounts of GATA-3 (mean MFI = 72.3), confirm-
ing that CD4+ T cells recognizing MMP-2 exhibited a TH2-like
phenotype (Figures 3C and 3D). Cord blood-derived naı¨ve
CD4+ T cells, gated on CD4+/CD45RA+/CD62L+ cells, were
used as a negative control (Figure 3D).Cancer Cell 19, 333–34Active MMP-2 Enzyme Is Required
for Differentiation of Naı¨ve
MMP-2-Specific CD4+ T Cells
into Inflammatory TH2 Cells
To determine whether the active full-
length protein was required for MMP-2-
specific CD4+ T cells to differentiate
toward an inflammatory TH2 phenotype,we primed naı¨ve CD4+ T cells (from 11 cord blood donors)
in vitro using autologous CD4- cells loaded with different sources
of MMP-2: overlapping peptides, or the protein in its active or
inactive conformation. The CD4- fraction was used as a source
of APCs to include any cell type that could potentially be involved
in priming. Peptide-specific responses of primed T cells were
measured after 15 days. The percentage of MMP-2-specific
CD4+ T cells secreting IL-4 (after background subtraction) was
significantly higher when cells were primed with the active
MMP-2 (mean = 2.38%), rather than with peptides (mean =
0.71%; mean of the individual differences = 1.34, p % 0.013)
or inactivated MMP-2, whether inactivation occurred by heating
(mean = 0.45% ; mean of differences = 1.80, p % 0.0002) or
using a specific inhibitor (mean = 0.12% ; mean of differences =
1.47, ns) (Figures 4A and 4B). Furthermore, active MMP-2-
primed cells produced less IFN-g and IL-2 compared with
inactiveMMP-2 or peptides (Figures 4A and 4B). Thus the inflam-
matory TH2 lineage commitment of MMP-2-specific CD4
+ T
lymphocytes depends on the presence of active MMP-2 both
as a source of antigen and as an endogenous TH2 conditioner.
Active MMP-2 Also Influences Other Tumor-Specific
T Helper Differentiation
To evaluate whether active MMP-2 also affected CD4+ T cell
differentiation specific for other MAA in a bystander fashion,6, March 15, 2011 ª2011 Elsevier Inc. 337
Figure 5. MMP-2 Influences Melan-A/MART-1- and NY-ESO-1-Specific T Helper Differentiation
(A) Cord blood-derived CD4+/CD25- cells were stimulated with autologous poly(I:C)-matured DCs pulsed with overlapping peptides spanning either Melan-A/
MART-1 or NY-ESO-1. Prior to poly(I:C) addition, DCs were incubated with or without MMP-2 (active or heat-inactivated) for 1 hr. MMP-2 enzymatic activity
was controlled (Figure S5C and S5D). After 15 days, CD4+ T cells were stimulated with the Melan-A/MART-1 or NY-ESO-1 peptide pools (2 mM) for 6 hr before
intracellular staining of cytokines. Percentages of antigen-specific CD4+ T cells, secreting indicated cytokines, are represented for all donors.
(B) Contour plots showing percentages of cytokine-producing CD4+ T cells are shown for representative donor CB45 primed toMelan-A/MART-1. Percentage of
secreting cells upon peptide stimulation was considered specific/positive when it exceeded bymore than twofold the background (cytokine-secreting cells in the
absence of stimulation) and had more than 0.5% of responding cells (after background subtraction) for at least one cytokine.
For each cytokine, two paired t tests were used to compare priming in the presence of active MMP-2 to either priming in the absence of active MMP-2 or with HI
MMP-2. The Bonferroni adjustment was used for multiple comparisons. p values% 0.025 (*) were considered statistically significant using a Bonferroni correction
for two comparisons.
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Melan-A/MART-1 or NY-ESO-1 using autologous poly(I:C)-
matured DCs pulsed with the corresponding overlapping
peptides. After 15 days, primed CD4+ T cells secreted IFN-g
(mean = 0.23% of secreting cells after background subtraction)338 Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc.and IL-2 (mean = 0.15%). CD4+ T cells specific for either tumor
associated antigen, secreted little IL-4 and IL-13 (mean =
0.75%and0.02%, respectively) (Figures 5Aand5B).On theother
hand, when DCs were preincubated with active MMP-2 before
maturation with poly(I:C), both Melan-A/MART-1- (Figures 5A
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MMP-2-Dependent Immune Deviation in Melanomaand 5B) and NY-ESO-1-specific (Figure 5A) primed CD4+ T cells
significantly failed to produce type 1 cytokines (p% 0.0004 and
p % 0.0073 for IFN-g and IL-2, respectively) upon peptide
restimulation (Figures 5A and 5B). Primed CD4+ T cells instead
significantly produced more IL-4 (mean = 2.50%; mean of
differences = 1.85, p % 0.0001) and IL-13 (mean = 0.08%;
mean of differences = 0.07, p % 0.0174) (Figures 5A and 5B).
In addition, CD4+ T cells primed using DCs preincubated
with heat-inactivated MMP-2 significantly secreted similar
cytokines than CD4+ T cells primed in the absence of MMP-2.
Accordingly, the former CD4+ T cells (primed with HI MMP-2)
were significantly different relative to CD4+ T cells primed in the
presence of active MMP-2 (mean of differences = 0.21 with
p % 0.0007 for IFN-g, mean of differences = 0.11 with p %
0.015 for IL-2 and mean of differences = 1.92 with p < 0.0001
for IL-4) (Figures 5A and 5B). Therefore, pre-exposure to active
MMP-2, but not to inactive MMP-2, confers DCs with the ability
to skew the differentiation of naı¨ve CD4+ T cells toward a TH2-
like phenotype, regardless of their antigen-specificity. Hence,
MMP-2 could participate in the detrimental TH2 skewing
observed in certain tumors, including melanoma, thus impairing
host antitumor immune responses (Botella-Estrada et al., 2005;
Lauerova et al., 2002; McCarter et al., 2005; Minkis et al., 2008;
Tatsumi et al., 2002).
MMP-2 Induces Inflammatory TH2 Cells in a Basophil-
Independent but DC-Dependent Manner
We next studied the cellular requirements underlying the inflam-
matory TH2 polarization of MMP-2-specific cells. Basophils,
recently described as APCs (Sokol et al., 2009), are thought to
play an important role in TH2 polarization by secreting factors
such as IL-4 or thymic stromal lymphopoietin (TSLP) (Ito et al.,
2005; Oh et al., 2007; Sokol et al., 2008). However, MMP-2
neither induced production of IL-4 nor TSLP by human basophils
(Figures S4A–S4C). In addition, MMP-2 did not increase the
expression of the basophil activation marker CD203c (Ocmant
et al., 2007), further demonstrating that MMP-2 did not stimulate
basophils (Figure S4A).
We next evaluatedwhether DCs could be involved in the polar-
ization of MMP-2-specific CD4+ T cells. Expression levels by
DCs of maturation markers CD40, CD80, CD83, CD86, HLA-
DR, and CCR7 were not significantly affected by either active
or inactive MMP-2 (not shown).
OX40L expressed on DCs can function as an inflammatory
TH2-skewing molecule (Ito et al., 2005). Both active and inacti-
vated MMP-2 significantly increased OX40L expression on
DCs (n = 9) irrespective of their maturation stage (Figures 6A
and 6B). However, differentiation into inflammatory TH2 cells
required pre-exposure of DCs to MMP-2 in its active conforma-
tion only (Figure 5), suggesting the involvement, in the polariza-
tion mechanism, of another molecule specifically sensitive to
active MMP-2.
Inhibition of IL-12 Production by MMP-2
Importantly, MMP-2-treated DCs produced significantly less
TH1-associated IL-12p70 (47.8% mean inhibition with 5 mg/ml
MMP-2; mean of differences = 41.7 with p % 0.001, n = 11
donors), in a dose-dependent manner, when stimulated with
the TLR3 agonist poly(I:C). The reduction in IL-12p70 was notobserved using inactivated MMP-2, MMP-2 peptides, rhPEX
(190 amino acid long C-terminal fragment of MMP-2 lacking
protease activity) or controls including glycerol (vehicle control
for MMP-2), DMSO (peptides diluted in DMSO) and a MMP-2-
specific inhibitor alone (Figure 7A). To assess whether MMP-2
diminished IL-12p70 levels by inhibiting DC production/secre-
tion or by directly degrading extracellular IL-12p70, we incu-
bated rhIL-12 for 24 hr in the presence or absence of MMP-2.
IL-12p70 levels remained the same in every condition (Fig-
ure S5A). Single chains IL-12p35 and IL-12p40 as well as
trypsin-exposed IL-12p70 were not recognized by the CBA kit
(Figure S5B), confirming its specificity for bioactive IL-12p70
and therefore strongly suggesting that IL-12 was not a substrate
for MMP-2 and that instead MMP-2 directly inhibited DCs to
produce IL-12p70. MMP-2 activity was controlled by measuring
its capacity to degrade MCP-3 (Figure S5C). Furthermore,
supernatants of MMP-2-exposed DCs did not affect IL-12p70
production by fresh DCs, suggesting that no cleaved part of
a MMP-2 substrate is directly responsible for this effect (Fig-
ure S5E). Following poly(I:C) activation, 4.33% ± 0.94 DCs ex-
pressed the IL-12p35 subunit, whereas only 1.5% ± 0.22 ex-
pressed it when preincubated with active MMP-2 (Figure 7B).
Thus, pre-exposure to active MMP-2 reduces DC production
of IL-12p35 (mean inhibition = 65%), thereby preventing the
formation of the bioactive IL-12p70. IL-12p40 production was
not affected overall (Figure 7B). Optimal IL-12p35 transcription
is thought to depend on STAT1 activation in human moDCs
(Gautier et al., 2005). As expected, STAT1 phosphorylation
was decreased when DCs were preincubated with active (p %
0.0047) but not inactive MMP-2 prior to poly(I:C) stimulation
(Figures 7C and 7D), suggesting that active MMP-2 inhibits IL-
12p35 production by preventing STAT1 phosphorylation.
MMP-2 binds integrins such as avb3 (Brooks et al., 1996),
aIIbb3 (Choi et al., 2008), or other b2 integrins (Stefanidakis
et al., 2003) and the scavenger receptor CD91 (Emonard et al.,
2004), all of which are expressed on human DCs. We therefore
tested whether MMP-2 signaled through such molecules to
block IL-12 production and induce OX40L expression. PEX
peptide, known to prevent MMP-2 binding to integrins such as
avb3 (Brooks et al., 1998), and blocking mAbs specific for
most of these receptors did not restore IL-12p70 production
by MMP-2-exposed DCs (not shown), suggesting that other
molecules may be involved.
STAT1 phosphorylation (Severa et al., 2006) and subsequent
IL-12 production (Gautier et al., 2005) can be induced by type I
IFN receptor triggering. We confirmed that IFN-b induced
IL-12p70 production, as blocking mAbs to IFN-b and its receptor
significantly inhibited IL-12p70 production and with a similar
magnitude as MMP-2 (Figure S5F). We consequently tested
involvement of this cytokine and its receptor in our system.
IFN-b signaling through its receptor leads to STAT1 phosphory-
lation (Severa et al., 2006), which triggers IL-12p35 transcription
and enhanced transcription of IFN-b itself through an amplifica-
tion loop (Decker et al., 2005; Gautier et al., 2005). Accordingly,
Poly (I:C)-matured DCs pre-exposed to active MMP-2 produced
decreased levels of IFN-b (Figure 7E). Strikingly, we found that
MMP-2-exposed DCs drastically lost expression of IFNAR1
chain of the receptor for type I IFNs (n = 7 donors, p % 0.001)
(Figures 7F and 7G). Furthermore, recombinant rhIFNAR1Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc. 339
Figure 6. MMP-2 Protein Induces OX40L Expression on DCs
Immature and poly(I:C)-matured DCswere incubated with active or HI MMP-2 (0.5 or 5 mg/ml) for 24 hr. MMP-2 enzymatic activity was controlled (Figure S5C and
S5D). OX40L expression was assessed by surface staining.
(A) Histogram plots are shown for representative donor HD1228. Isotype control is represented in tinted gray.
(B) Mean fluorescent intensities are represented for all nine donors tested.
For immature and mature DCs, paired t tests were used to compare low and high values of glycerol, active MMP-2 and inactive MMP-2. p values% 0.0167 (*)
were considered statistically significant using a Bonferroni correction for three comparisons for each DC type.
See also Figure S4.
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degraded by MMP-2 (Figure 7H). Therefore, MMP-2 cleaves
IFNAR1 on DCs leading to loss of IL-12p35 production through
reduction of STAT1 phosphorylation.
In summary, both active and inactive MMP-2 induce OX40L
expression by DCs while active MMP-2 inhibits IL-12p35
production, and subsequent IL-12p70 formation by degrading
IFNAR1.
MMP-2-Specific CD4+ T Cell Differentiation Depends
on IL-12 and OX40L Expression by DCs during Priming
To testwhetherOX40Land/or IL-12p70weredirectly responsible
for inflammatory TH2 polarization of MMP-2-specific T cells,340 Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc.naı¨ve CD4+ T cells from 19 cord blood donors were primed by
autologous poly(I:C)-matured DCs pulsed with the active MMP-
2 protein. As expected, primed MMP-2-specific CD4+ T cells
secreted IL-4 and TNF-a corresponding to the inflammatory
TH2 phenotype observed so far. However, when exogenous
rhIL-12 was added throughout priming, MMP-2-specific T cells
partially reverted their phenotype toward a TH1-like profile, i.e.,
secreting less IL-4 (p % 0.0001; n = 19) and more IFN-g (p =
0.022; n = 19). These results are consistent with the concept
that lack of IL-12p70 is critical for inflammatory TH2differentiation
of MMP-2-specific CD4+ T cells (Figures 8A and 8B). When naı¨ve
T cells were primed in the presence of anti-OX40L, MMP-2-
specific cells secreted less IL-4 (p % 0.003; n = 10) and more
Figure 7. MMP-2-Dependent Mechanism
Blocking IL-12 Production by DCs
Immature DCs were incubated with MMP-2 (0.5 or
5 mg/ml) and poly(I:C)-matured 1 hr later. IL-12p70
levels were measured 16 hr later.
(A) Results are represented as a percentage of IL-
12p70 levels, measured by CBA, produced when
DCs were incubated with poly(I:C) only (n = 11).
(B) For intracellular staining of IL-12p35 and
IL-12p40 chains, Brefeldin A was added 4 hr after
poly(I:C) activation and cells were stained after an
additional 12 hr incubation. Numbers in the upper
right quadrants are the percentages of each pop-
ulation for a representative donor (n = 3).
(C and D) Immature DCs were incubated with
MMP-2 for 1 hr (5 mg/ml) before poly(I:C) matura-
tion. Intracellular staining of phosphorylated
(Y701) STAT1 (P-STAT1) was performed 3 hr later.
A representative donor (C) and results for all
three donors (D) are shown. Active MMP-2 only
significantly inhibits STAT1 phosphorylation (p %
0.0047). Results are shown as mean ± SD.
(E) Immature DCs were incubated with MMP-2
and poly(I:C)-matured 1 hr later. IFNb levels were
measured by ELISA 16 hr later. Results are repre-
sented as a percentage of IFNb levels produced
when DCs were incubated with poly(I:C) only
(n = 9). Results are shown as mean ± SD.
(F and G) 106DCs/lane were treated with 0.1 mg
MMP-2 or controls. Poly(I:C) was added 1 hr later.
IFNAR1 protein expression was detected the next
day by western blot analysis using a rabbit mono-
clonal antibody. A representative donor (F) and
results for all seven donors (G) are shown.
(H) The rhIFNAR1 (5 mg ;z110 kDa) was incubated
overnight with 0.3 mg MMP-2 before performing
western blot analysis for IFNAR1. The second
band (around 90 kDa) and the third band
(25 kDa) very likely correspond to either a
degraded form of the protein still recognized by
the Ab or a contaminant present in the commercial
protein preparation and nonspecifically recog-
nized by the Ab.
MMP-2 enzymatic activity was controlled (Figures
S5C and S5D).
Statistical analysis: A: Two paired t tests were
used to compare low levels of glycerol with low
levels of active MMP-2 and high levels of glycerol
with high levels of active MMP2; E: For low and
high levels, three comparisons were carried out
(glycerol to active MMP-2, glycerol to HI MMP-2
and active MMP-2 to active MMP-9); G: three
comparisons were carried out (glycerol to active
MMP-2, glycerol to HI MMP-2 and active
MMP-2 to HI MMP-2). For the two comparisons,
p values % 0.025 (*) were considered statistically
significant; for the three comparison analyses,
p values% 0.0167 (*) were considered statistically
significant.
See also Figure S5.
Cancer Cell
MMP-2-Dependent Immune Deviation in MelanomaIFN-g (p = 0.023; n = 10) than CD4+ T cells primed without addi-
tional IL-12 (Figures 8A and 8B). Addition of both rhIL-12 and
anti-OX40L during priming triggered MMP-2-specific CD4+
T cells secreting less IL-4 (p % 0.002; n = 10) and more IFN-g
(p% 0.006; n = 10) than anti-OX40L alone (Figure 8B), indicatingthat both molecules are involved in MMP-2-specific CD4+ T cell
polarization.
IL-4 is critical for TH2 differentiation in many models (Sokol
et al., 2008; Swain et al., 1990). We next primed naı¨ve MMP-2-
specific CD4+ T cells to active MMP-2 while blocking potentialCancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc. 341
Figure 8. MMP-2-Specific CD4+ T Cell Differentiation Depends on IL-12p70 and OX40L Expression by DCs
(A) Cord blood-derived CD4+/CD25- cells from 19 donors were stimulated with autologous DCs previously loaded with active MMP-2 (MMP-2 enzymatic activity
was controlled; Figures S5C and S5D) for 15 days in the absence or in the presence of exogenous rhIL-12 (10 ng/ml) or blocking mAb for OX40L or IL-4 (10 mg/ml).
CD4+ T cells were then stimulated with the MMP-2 peptide pool (2 mM) for 6 hr before intracellular staining of cytokines. Contour plots representing cytokine
production by CD4+ T cells are shown for donor CB31 CD4+ T cells primed to MMP-2 alone, or together with rhIL-12, anti-OX40L mAb or anti-IL-4 mAb (not
shown).
(B) Percentages of MMP-2-specific CD4+ T cells, secreting indicated cytokines, are represented for all donors.
For each cytokine, five paired t tests were used to compare ‘‘no conditioning’’ versus various conditions. p values% 0.01 (*) were considered statistically signif-
icant using a Bonferroni correction for five comparisons.
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identical inflammatory TH2 phenotype (n = 8) (Figure 8B), con-
firming that, in this TH2 differentiation model, IL-4 is not a major
determinant. Therefore, inflammatory TH2 polarization of MMP-
2-specific T cells is dependent upon both IL-12p70 and
OX40L, but not on IL-4.
In summary, our data show that MMP-2 induces priming of
TH2 inflammatory CD4
+ T cells, by diminishing IL-12 production
(through degradation of type 1 IFN receptor) and inducing OX40L342 Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc.expression by DCs. Therefore, MMP-2 acts as an endogenous
type 2 conditioner in humans.
DISCUSSION
The first two subsets described of effector CD4+ T cells were the
TH1 and TH2 subpopulations (Mosmann and Coffman, 1989).
Both cells were shown to mediate anticancer functions (Nishi-
mura et al., 1999), but IFN-g-secreting TH1 cells appeared
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MMP-2-Dependent Immune Deviation in Melanomato be superior in inducing memory cytotoxic responses and
strong cellular immunity (Nishimura et al., 2000). TH1 cells are
characterized by their production of IFN-g and, to a lesser
extent, IL-2. IL-12p70 produced by APCs, particularly activated
DCs, as well as IFN-g produced by NK cells and T cells, polarize
CD4+ T cells toward the TH1 cell differentiation program through
STAT1 and T-bet (Szabo et al., 2000). In contrast, TH2 cells
mediate host defense against extracellular parasites including
helminths and are important in the induction and persistence
of allergic diseases. Conventional TH2 cells are classically
defined as producers of IL-4, IL-5, IL-10, and IL-13 but themech-
anism(s) underlying induction of TH2 differentiation has remained
unclear.
IL-4, by inducing GATA-3 expression, is usually described as
essential for TH2 differentiation (Sokol et al., 2008; Swain et al.,
1990). Cellular sources of IL-4 for TH2 differentiation have not
been clearly established. Granulocytes such as basophils readily
produce IL-4 after crosslinking of their Fc3RI receptors and have
been proposed to be responsible for TH2 differentiation in
several models (Falcone et al., 1996; Sokol et al., 2008).
MMP-2 did not activate basophils (assessed by IL-4 and TSLP
production as well as CD203c expression) (Figure S4A–S4C),
suggesting that these cells were not involved in this model.
Moreover, MMP-2-induced type 2 differentiation does not
appear to depend on IL-4 as naı¨ve MMP-2-specific CD4+
T cells primed in the presence or in the absence of a blocking
antibody specific for IL-4 gave rise to type 2 CD4+ T cells with
a similar profile (Figures 8A and 8B). This observation is in accor-
dance with accumulating in vivo studies indicating that, in some
settings, IL-4 is not essential for TH2 differentiation (Everts et al.,
2009; Jankovic et al., 2000; Steinfelder et al., 2009). A default
mechanism could also explain TH2 differentiation, where the
lack of TH1-polarizing signal, namely IL-12, would be sufficient
and/or necessary (Minkis et al., 2008; Moser and Murphy,
2000). We found that active MMP-2 inhibited IL-12 production
by DCs (Figures 7A and 7B), which was in part responsible for
the MMP-2-induced type 2 polarization. Indeed, supplementing
the priming cultures of MMP-2-specific CD4+ T cells with rhIL12,
even at doses as low as 1 ng/ml (not shown), induced lower
percentages of IL-4-secreting T cells and more IFN-g-secreting
cells (Figures 8A and 8B). TSLP leads to TH2 cell recruitment and
allergic inflammation (Liu et al., 2007). Basophils (Sokol et al.,
2008), epithelial cells (Soumelis and Liu, 2004), or DCs (Ito
et al., 2005; Liu, 2006; Watanabe et al., 2004) can be sources of
TSLP. TSLP contributes to TH2 immunity either by inhibiting
TH1 differentiation, by acting directly on T cells to promote TH2
differentiation or by activating DCs. Stimulation of DCs with
TSLP, in the absence of IL-12p70, induces upregulation of the
costimulatory molecule OX40L and can promote differentiation
of naı¨ve T cells into cells secreting IL-4, IL-5, IL-13, and TNF-a,
named inflammatory TH2 (Ito et al., 2005; Soumelis et al., 2002).
MMP-2-specific CD4+ T cells secreted IL-4, IL-13 and TNF-a,
but no IL-10, consistent with such an inflammatory TH2 profile.
Interestingly, MMP-2 did not activate basophils to secrete
TSLP (nor IL-4) (Figure S4). On the other hand, MMP-2 induced
DCs to express OX40L (Figures 6A and 6B), in a TSLP-indepen-
dent manner (not shown). We showed that inflammatory TH2
differentiation of MMP-2-specific cells also relied on OX40L
expression (Figures 8A and 8B). OX40 signaling in CD4+ T cellscan directly induce type 2 lineage commitment by inducing
NFATc1, which triggers IL-4 production and subsequent
GATA-3 expression (So et al., 2006; Yu et al., 2009). MMP-2-
induced type 2 differentiation likely works differently as we
showed that IL-4 was not a major determinant in this model. Of
note, addition of both rhIL-12 and anti-OX40L blocking mAb
during priming induced MMP-2-specific CD4+ T cells secreting
significantly less IL-4 andmore IFN-g than anti-OX40L alone (Fig-
ure 8B), indicating that both molecules were involved in MMP-2-
induced type 2 differentiation by triggering additive effects.
We found that MMP-2 degrades IFNAR1 (Figures 7F–7H),
constituting one chain of the heterodimeric type I IFN receptor.
The IFNAR1 chain, described here as a substrate for MMP-2,
is essential for signaling (Decker et al., 2005). When cleaved,
the type I IFN amplification loop is abrogated, explaining the
reduction of IFN-b secreted byMMP-2-exposedDCs (Figure 7E).
Type I IFN receptor signaling triggers STAT1 phosphorylation
(Severa et al., 2006), which, in turn, also induces IL-12p35 tran-
scription (Gautier et al., 2005). As a result, bioactive IL-12p70
formation is inhibited and cannot exert its function in TH1 differ-
entiation. Through this mechanism, MMP-2 acts as an endoge-
nous type 2 ‘‘conditioner’’.
TNF+/IL10- TH2 cells are thought to represent the pathogenic
TH2 cells that cause allergic inflammation, in contrast to the
conventional IL-10-producing cells. Many potent allergens
have intrinsic protease activity (Grobe et al., 1999; Kheradmand
et al., 2002) and secreted proteases are essential for the infec-
tious and reproductive cycles of helminthes (McKerrow et al.,
2006). Recent studies showed that the T2 ribonuclease derived
from soluble egg antigens of the parasitic helminth Schistosoma
triggers potent TH2 responses by conditioning mouse DCs
(Everts et al., 2009; Steinfelder et al., 2009). One can speculate
that the innate immune systemmight have evolved amechanism
to detect abnormal proteases associated with helminth infection
that could then be triggered by other proteases, such as aller-
gens or in this case MMP-2. Our results clearly showed that an
enzyme-induced TH2-conditioning directly resides in the intrinsic
enzymatic activity rather than solely in the active conformation of
MMP-2.
MMP-2 also acts as a type 2 conditioner for CD4+ T cells
recognizing other MAA (Figures 5A and 5B), indicating that
MMP-2 plays a dominant role in biasing the response against
otherwise TH1-inducing tumor antigens. Our in vitro results
suggest that increased MMP-2 secretion may locally influence
the induction of immune responses and skew them toward
type 2 responses. Accordingly, MMP-2-specific CD4+ T cell
responses tended to be found in TILs from patients exhibiting
a poorer clinical outcome (Figure S1B). MMP-2 might therefore
partially explain the observed prevalence, at least in some
studies, of detrimental type 2 responses in various cancers
including melanoma.
Our findings collectively support the idea that the protumoral
MMP-2 protein represents a good candidate to target in immu-
notherapy to treat melanoma patients, since it can induce both
broad CD4+ and CD8+ T cell responses. Furthermore, elucida-
tion of mechanisms underlying TH2 polarization, including the
one identified in this study, opens the way to designing immune
strategies for inducing effective antitumor TH1-like responses to
treat cancer patients.Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc. 343
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Human Tissue Specimens
Tumor-infiltrating lymphocytes (TILs) were provided by Pr. F. Jotereau and
B. Dre´no. Following informed consent, TILs were obtained from tumor-
invaded lymph nodes of melanoma patients (stage IIIb). These patients subse-
quently received autologous TILs and IL-2 infusions in a clinical trial (Labarriere
et al., 2002). This protocol was approved by the Institutional Ethics Committee
and registered with the regulatory state authority in France (Nantes). Moreover,
TILs were expended in a specific genetic and cellular therapy unit (UTCG;
CHRU, Nantes, France) under good manufacturing practice (GMP) conditions.
Blood from healthy donors was purchased from the New York Blood Center.
Of note, all samples, from donors and patients, have been deidentified prior
to the analysis.
Reagents
Purified human MMP-2 (mixture of the proenzyme [50%] and the active form
[50%]) was purchased from Biomol. The MMP-2 enzyme was inactivated
either by heating to 56C for 45min or by addition of the MMP-2 inhibitor III
at 100nM (Calbiochem) for 20 min. rhPEX was purchased from Genway.
rhMMP-9 (Calbiochem) was used as a mixture of the proenzyme (50%) and
the active protein (50%). Overlapping peptides (20 amino acid long overlap-
ping of 10) spanning proMMP-2 sequence were from Proimmune (>80%
pure). Lyophilized peptides were reconstituted in DMSO and were used either
individually (2 mM) or as a pool (2 mM each). rhGM-CSF was purchased from
Immunex. rhIL-12, rhIL-4, rhIL-7, and rhIL-2 were from R&D Systems. The
kits used for basophil isolation and IFN-g-secreting cell enrichment (Miltenyi
Biotec) were used according to the manufacturer’s instructions.
Antibodies
Allophycocyanin-conjugated antibody to CCR-7 (150503) was purchased
from R&D Systems. Unconjugated (10 mg/ml for blocking experiments) or
phycoerythrin-conjugated antibody to OX40L (11C3.1) was from Biolegend.
Blocking antibody to IL-4 (8F12; 10 mg/ml) was from Acris. Antibodies to
human Vb chains covering 70% of the repertoire (IOTest Beta Mark; Beckman
Coulter) were used according to the manufacturer’s intructions. Fluorescein
isothiocyanate-conjugated antibody to IL-12p35/IL-12p70 (B-T21) and
IFNAR1 (EP899Y) were from Abcam. Phycoerythrine-conjugated antibodies
to IL-12p40/IL-12p70 (C8.6), IL-10 (B-T10), CD203c (FR3-16A11) were from
Miltenyi Biotec. Blocking antibody to HLA-DQ (SPV-L3; 20 mg/ml) was from
NeoMarkers. Blocking antibodies to HLA-DP (B7/21; 20 mg/ml) or HLA-DR
(L243; 20 mg/ml), phycoerythrine-conjugated antibodies to phosphorylated
(Y701) STAT1 (4a), GATA-3 (L50-823), IL-2 (MQ1-17H12), IL-4 (8D4-8), IL-5
(JES1-39D10), IL-13 (JES10-5A2), TNF-a (MAb11), IFN-g (25723.11), perforin
(dG9), GranzymeB (GB11), CD40 (5C3), CD80 (L307.4), CD83 (HB15e), CD86
(IT2.2), HLA-DR (TU36), fluorescein isothiocyanate-conjugated antibodies to
CD45RA (HI100) and CD45RO (UCHL1), and antibody to CD4 (RPA-T4) were
purchased from BD Biosciences PharMingen. Alexa fluor 488-conjugated
antibody to IL-17 (eBio64DEC17), phycoerythrine-conjugated antibody to
T-bet (4B10) and allophycocyanin-conjugated antibody to CD62L (DREG-56)
were from eBioscience. Antiboby to b-actin (C-2) was from Santa Cruz
Biotechnology.
T Cell Culture, Stimulation and Priming
Peripheral blood mononuclear cells (PBMCs) were purified from healthy
donor- (HD) or cord blood (CB) donor-derived buffy coats (New York Blood
Center) by Ficoll-Paque Plus (GE Healthcare) centrifugation. CD4+/CD25- cells
were enriched (>90%) by magnetic cell sorting (Miltenyi Biotec) and primed/
stimulated for 12–15 days either with irradiated (35 Gy) autologous CD4- cells
or with autologous mature DCs in IMDM (GIBCO) supplemented with 1 mM
HEPES (Life Technologies), 2 mM L-glutamine (Sigma), streptomycin
(100 UI/ml)/penicillin (100 mg/ml) (Sigma) and 5% heat inactivated pooled
human serum (PHS; Valley Biomedical) in the presence of rhIL-2 (10 UI/ml)
and IL7 (5 ng/ml) (R&D Systems). Antigen presenting cells (CD4- cells or
DCs) were loaded either with peptides (2 mM) or with the MMP-2 protein
(10 mg/ml) for 2 and 5 hr, respectively. DCs were matured using the TLR3
agonist poly(I:C) at 5 mg/ml/106 DCs (Amersham). To generate T cell clones,
we originally relied on our published methodology (Godefroy et al., 2006,344 Cancer Cell 19, 333–346, March 15, 2011 ª2011 Elsevier Inc.2007), involving enrichment of IFN-g-secreting cells upon short-term culture
and peptide stimulation to generate MMP-2 responsive clones. Although
MMP-2-specific cells could be isolated, it was realized that IFN-g secretion
was marginal compared with their secretion of IL-4 and TNF-a. IFN-g-
secreting cells in response to MMP-2 peptide pool were enriched by cyto-
kine-guided magnetic cell sorting (Miltenyi Biotec) and cloned the following
day by limiting dilution in the presence of irradiated allogeneic PBMCs,
1 mg/ml phytohemagglutinin-L (Sigma) and 150 UI/ml rhIL-2. Tumor infiltrating
lymphocytes (TILs) were provided by Pr. F. Jotereau and B. Dre´no. They were
obtained from tumor-invaded lymph nodes of melanoma patients (stage IIIb)
and expanded ex vivo. These patients received autologous TILs and IL-2 infu-
sions in a clinical trial (Labarriere et al., 2002). This protocol was approved by
the Institutional Ethics Committee and registered with regulatory state
authority in France (Nantes).
Dendritic Cell Preparation and Activation
PBMCswere purified from healthy- (HD) or cord blood- (CB) donors and plated
at 40.106 cells/10 ml/dish in complete IMDMwith 5% PHS. Cells were allowed
to adhere for 2 hr at 37C. Nonadherent cells were removed. The monocyte-
enriched fraction was supplemented with 100 UI/ml rhGM-CSF and
300 UI/ml rhIL-4 (R&D Systems) on days 0, 2, and 4. Immature DCs were har-
vested on day 5 and matured using poly(I:C) at 5 mg/ml/106 DCs (Amersham).
Secretion of IL-12p70, TNF-a, IL-1b, IL-6, IL-8, and IL-10 was assessed on
both immature and mature DCs using the Human Inflammatory Cytokine
Cytometric Bead Array (BD PharMingen).
Enzyme-Linked Immunosorbent Assay
Activation of T cell clones (10,000 cells/100 ml/well), polyclonal T cell popula-
tions (100,000 cells/100 ml/well), DCs (50,000 cells/100 ml/well), and basophils
(10,000 cells/100 ml/well) was determined by ELISA. IFN-g (BioSource),
TNF-a (BioSource), IL-4 (BioSource), TSLP (Quantikine; R&D Systems),
IFN-b (VeriKine; PBL interferon source), and MCP-3 (DuoSet; R&D Systems)
contents in supernatants were measured according to the manufacturer’s
instructions.
Intracellular Staining
T-bet and GATA-3 expression was measured on resting T cells. Cells were
fixed (4% paraformaldehyde for 10 min at RT), permeabilized with 0.1%
saponin, and stained for intracellular transcription factors. Cytokine produc-
tion by T cells was also assessed by intracellular staining. T cells were stimu-
lated with 2 mM overlapping peptides. After 1 hr, 10 mg/ml brefeldin A was
added to the cells. Five hours later, T cells were stained for surface markers,
fixed, permeabilized, and stained for intracellular cytokines (TNF-a, IFN-g,
IL-2, perforin, granzymeB, IL-4, IL-5, IL-10, IL-13, and IL-17). Antigen-speci-
ficity was defined by the percentage of cells secreting cytokine as long as it
exceeded background (cytokine-secreting cells in the absence of peptide
stimulation) by more than 2-fold and consisted of more than 0.5% of respond-
ing cells following subtraction of background for at least one cytokine.
It was not uncommon to find relatively high background levels of IL-4 and
TNF-aproducing T cells, likely due to the fact that these highly sensitive cells
continued to produce cytokine up to 2–3 weeks after stimulation. For assess-
ment of IL-4 production by basophils, brefeldin Awas added simultaneously to
stimulation. For intracellular staining of IL-12p35, IL-12p40, and phosphory-
lated STAT1, immature DCs were incubated with or without MMP-2 as
described in figure legends. After 1 hr, 5 mg/ml poly(I:C) was added to activate
immature DCs. For monitoring IL-12 subunits, brefeldin A was added 4 hr after
poly(I:C) addition. DCs were then cultured for 12 hr, fixed, permeabilized, and
stained for intracellular IL-12. For detection of STAT1 phosphorylation on
Y701, DCs were fixed 3 hr after poly(I:C) addition, permeabilized and stained.
Data were acquired with FACScalibur cytometer (BD Biosciences) and
analyzed using FlowJo software.
Western Blots
IFNAR1 and b-actin were detected by western blot analysis using rabbit and
mouse mAbs, respectively. HRP-linked anti-rabbit (Cell Signaling) or anti-
mouse (Amersham Biosciences) IgG were used as secondary Abs before
chemiluminescent detection (ECL Plus, Amersham Biosciences).
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Separate analyses were performed for each experiment individually. Analyses
take into account paired observations within donors when appropriate (e.g.,
MMP-2 versus no MMP-2, active versus inactive, active versus peptides).
For three-group comparisons (i.e., MMP-2, Melan-A, NY-ESO-1), analyses
of variance were performed for an overall comparison among independent
groups, and t tests were then used for specific pairwise comparisons between
groups. Within each analysis, p values were adjusted for multiple comparisons
using a Bonferroni correction. For analyses in which each of two groups was
compared with a third group (i.e., two comparisons, with no overall test of
the three groups), two t tests were performed, using the Bonferroni adjustment
for the two analyses. Two-sided statistical tests were performed at an overall
alpha-level of 0.05, with adjustments for multiple comparisons, as described
above. Details for each analysis are provided in the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and one table and can be found
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